JMP Securities Reiterates a Buy Rating on Retrophin

By Jason Carr

In a report released today, Liisa Bayko from JMP Securities reiterated a Buy rating on Retrophin (NASDAQ: RTRX). The company’s shares opened today at $16.07.

According to, Bayko is ranked 0 out of 5 stars with an average return of -4.8% and a 32.6% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.

Retrophin has an analyst consensus of Strong Buy, with a price target consensus of $28.

Based on Retrophin’s latest earnings report from March 31, the company posted quarterly revenue of $43.4M and quarterly net profit of $11.22M. In comparison, last year the company earned revenue of $197M and had a net profit of $105.6M.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RTRX in relation to earlier this year. Most recently, in March 2016, Jeffrey Meckler, a Director at RTRX bought 5,000 shares for a total of $76,550.

Retrophin, Inc. is a fully integrated biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.